Part,  Chapter, Paragraph

  1    I,     3.  3    |                 population growth in the E.U. leads to shifts in the
  2    I,     3.  4    |          References~ ~Beets G, Dourleijn E, Liefbroer A, Henkens K (
  3    I,     3.  4    |                NIDI, Den Haag.~ ~Bloom D E, Trussell J (1984): What
  4    I,     3.  4    |        infecondité en Europe, in A. Blum e J. L. Rallu (eds) Démographie
  5   II,     5.  2.  7|               S1-16.~Puska P, Vartiainen E, Tuomilehto J, Salomaa V,
  6   II,     5.  2.  7|                 M, Tolonen H, Ruokokoski E, Amouyel P (1999): Contribution
  7   II,     5.  3.  9|                  Baili P, Quinn M, Mugno E, Capocaccia R, Grosclaude
  8   II,     5.  3.  9|               Micheli A, Berrino F, Paci E, Verdecchia A, Pierotti
  9   II,     5.  3.  9|          Capocaccia R, Martinez C, Mugno E, Coebergh JW, Baili P, Verdecchia
 10   II,     5.  4.  8|                Lapetra ML, Wei L, Kelley E and the Members of the HCQI
 11   II,     5.  4.  8|                   421-7~Pruna S, Stanciu E, Macarie A, Pruna A, Ionescu-Tirgoviste
 12   II,     5.  5.  3|                  C, Schulze B, Bertocchi E, Rossi G, Ghilardi A, Pioli
 13   II,     5.  5.  3|                Nakonezny PA, Lescouflair E (2007): Antipsychotic medication
 14   II,     5.  5.  3|                2nd edition - Jané-Llopis E, Anderson P eds.).~Fang
 15   II,     5.  5.  3|             Knapp M, McDaid D, Mossialos E, Thornicroft G (2007): Mental
 16   II,     5.  5.  3|            Psychiatry 188:193.~Lindström E, Eberhard J, Neovius M,
 17   II,     5.  5.  3|                 S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach
 18   II,     5.  5.  3|          Silverstone T, Smith G, Goodall E (1988): Prevalence of obesity
 19   II,     5.  5.  3|               Reports, Nov-Dec.~Fombonne E (2005): Epidemiology of
 20   II,     5.  5.  3|      Disabilities, London.~Sánchez-Valle E et al (2007): Estimating
 21   II,     5.  5.  3|              Epilepsia 21:235-242.~Beghi E, Cornaggia CM, and the RESt-1
 22   II,     5.  5.  3|            Epilepsia 43:1076-1083.~Beghi E (2004): Aetiology of epilepsy.
 23   II,     5.  5.  3|            Edited by: Shorvon S, Perucca E, Fish D, Dodson E.) Oxford,
 24   II,     5.  5.  3|                Perucca E, Fish D, Dodson E.) Oxford, Blackwell Science;
 25   II,     5.  5.  3|                 Science; p. 50-63.~Beghi E, Sander JW (2005): Epilepsy
 26   II,     5.  5.  3|            Edited by: Shorvon S, Perucca E, Fish D, Dodson E.) Oxford,
 27   II,     5.  5.  3|                Perucca E, Fish D, Dodson E.) Oxford, Blackwell Science;
 28   II,     5.  5.  3|                 21-42.~Forsgren L, Beghi E, Oun A, Sillanpaa M (2005):
 29   II,     5.  5.  3|              suppl 11):S15-S19.~Olafsson E, Hauser WA, Gudmundsson
 30   II,     5.  5.  3|             Epilepsia 39:89-92.~Olafsson E, Ludvigsson P, Gudmundsson
 31   II,     5.  5.  3|                 239-148.~Tomson T, Beghi E, Sundqvist A, Johannessen
 32   II,     5.  5.  3|                   Van den Broek M, Beghi E, for the RESt-1 group (2004):
 33   II,     5.  5.  3|               210.~Benito-Léon J, Martín E, Vela L et al (1998): Multiple
 34   II,     5.  5.  3|             Deomina T, Favorova O, Gusev E, Sudomoina M, Turetskaya
 35   II,     5.  5.  3|               Koch-Henriksen N, Stenager E (2004): Trends in survival
 36   II,     5.  5.  3|               Brønnum-Hansen H, Stenager E, Hansen T, Koch-Henriksen
 37   II,     5.  5.  3|               Lancet 7;268-277.~Ekestern E, Lebhart G (2004). Mortality
 38   II,     5.  5.  3|                1033–1040.~Ford HL, Gerry E, Airey CM, et al (1998):
 39   II,     5.  5.  3|                  605–610.~Ford HL, Gerry E, Johnson M, Williams R (
 40   II,     5.  5.  3|          Accessed June 14 2005.~Granieri E, Malagú S, Casetta I, et
 41   II,     5.  5.  3|                 186.~Grønlie SA, Myrvoll E, Hansen G, et al (2000):
 42   II,     5.  5.  3|                 N, Rasmussen S, Stenager E, et al (2001). The Danish
 43   II,     5.  5.  3|                  185.~Mor u T, eaManceau E, Lucas B, Lemesle M, Urbinelli
 44   II,     5.  5.  3|           Ranzato F, Perini P, Tzintzeva E et al (2003): Increasing
 45   II,     5.  5.  3|          Aarsland D, Larsen JP, Tandberg E, Laake K (2000): Predictors
 46   II,     5.  5.  3|                 P, Maggi S, Perissinotto E, Grigoletto F, Amaducci
 47   II,     5.  5.  3|               Bergareche A, De La Puente E, Lopez de Munain A, Sarasqueta
 48   II,     5.  5.  3|                 CE, Zobkiw RM, Gullaksen E (1995): Quality of life
 49   II,     5.  5.  3|                 R, Gamberini G, Granieri E, Benassi G, Naccarato S,
 50   II,     5.  5.  3|                Szucs T, Rathay B, Scholz E, Oertel WH (1998): The economic
 51   II,     5.  5.  3|             Privaten Krankenversicherung e 46(4):122-128.~Elbaz A,
 52   II,     5.  5.  3|                 217(2):169-174.~Granieri E, Carreras M, Casetta I,
 53   II,     5.  5.  3|               Govoni V, Tola MR, Paolino E, Monetti VC, De Bastiani
 54   II,     5.  5.  3|                  339.~Horstink M, Tolosa E, Bonuccelli U, Deuschl G,
 55   II,     5.  5.  3|                  Campenhausen S, Spottke E, Siebert U, Dodel R (2005):
 56   II,     5.  5.  3|                  264.~Rosati G, Granieri E, Pinna L, Devoto MC (1979):
 57   II,     5.  5.  3|                  308.~Rosati G, Granieri E, Pinna L, Aiello I, Tola
 58   II,     5.  5.  3|              Brain 123:2297-2305.~Singer E (1973): Social costs of
 59   II,     5.  5.  3|      Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M (
 60   II,     5.  6.  6|              References~ ~Altman R, Asch E, Bloch D, Bole G, Borenstein
 61   II,     5.  6.  6|                   Machold K, Martin-Mola E, Nielsen H, Silman A, Smolen
 62   II,     5.  6.  6|          Arthritis Rheum 41:778-799~Levy E, Ferme A, Perocheau D, Bono
 63   II,     5.  6.  6|                   Goldsmith CH, Jamieson E, Torrance GW, Tugwell P (
 64   II,     5.  6.  6|                 Webb R, Asten P, Barrett E, Lunt M, Scott D, Silman
 65   II,     5.  6.  6|                 D, Veale DJ, Martin-Mola E (2004): Musculoskeletal
 66   II,     5.  6.  6|                 1st ed. (Edited by Nancy E Lane and Philip N Sambrook)
 67   II,     5.  7.  7|                 Claris-Appiani A, Taioli E, et al (2003): Epidemiology
 68   II,     5.  7.  7|                  106(6):703-10.~Ejerblad E, Fored CM, Lindblad P, Fryzek
 69   II,     5.  7.  7|        Netherlands, June 2007.~Esbjorner E, Berg U, Hansson S (1997):
 70   II,     5.  7.  7|                1047.~Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004):
 71   II,     5.  7.  7|                  Bindman AB, Vittinghoff E, Kanaya AM, Kushel MB (2007):
 72   II,     5.  8.  7|                Moreau D, Kalaboka S, Gay E, Bonnefoy X, Carrozzi L,
 73   II,     5.  8.  7|                   Nizankowska-Mogilnicka E, on behalf of BOLD Collaborative
 74   II,     5.  8.  7|                 424.~ ~Furhman C, Jougla E, Nicolauu J, Eilstein D,
 75   II,     5.  8.  7|                 M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski
 76   II,     5.  8.  7|                  G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum
 77   II,     5.  8.  7|              Hallin R, Ulrik CS, Brondum E,Nieminen MM, Aine T, Bakke
 78   II,     5.  8.  7|            Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM (2006):
 79   II,     5.  8.  7|              Borg S, Ericsson A, Jonsson E, Lundback B (2002): Costs
 80   II,     5.  8.  7|                   Johannessen A, Omenaas E, Bakke P, Gulsvik A (2005):
 81   II,     5.  8.  7|                Bjerg-Backlund A, Ronmark E, Larsson LG, Lundback B. (
 82   II,     5.  8.  7|          Lindberg A, Jonsson AC, Ronmark E, Lundgren R, Larsson LG,
 83   II,     5.  8.  7|          Eriksson B, Larsson LG, Ronmark E, Sandstrom T, Lundback B (
 84   II,     5.  8.  7|                  A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E,
 85   II,     5.  8.  7|           Ronmark E, Jonsson AC, Jonsson E, Larsson LG, Andersson S,
 86   II,     5.  8.  7|                 J, Montemayor T, Gobartt E, Martin A, Alvarez-Sala
 87   II,     5.  8.  7|                349: 1498–1504.~ ~Murtagh E, Heaney L, Gingles J, Shepherd
 88   II,     5.  8.  7|                20: 443-453.~Niederlander E. Health (2006): In “Population
 89   II,     5.  8.  7|            Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling
 90   II,     5.  9.  7|                   7, 954-960~ ~Compalati E, Penagos M, Henley K, Canonica
 91   II,     5.  9.  7|              Erwin EA, Custis N, Ronmark E, Wickens K, Sporik R, Woodfolk
 92   II,     5.  9.  7|           Holgate ST, Price D, Valovirta E (2006): Asthma out of control?
 93   II,     5.  9.  7|         Bettoncelli G, Cricelli C, Sessa E, Mazzaglia G, Canonica GW,
 94   II,     5.  9.  7|                 62(5):569-71)~ ~Migliore E (2007): Prevalence of respiratory
 95   II,     5. 10.Acr|              Diseases~IgE~Immunoglobulin E~SCF~Scientific Committee
 96   II,     5. 10.  5|               Nuts and products thereof (e)~- Celery and products thereof~-
 97   II,     5. 10.  5|                  beverages; lactitol.~ ~(e) nuts used for making distillates
 98   II,     5. 10.  7|         allergen-specific immunoglobulin E antibodies from 1973 to
 99   II,     5. 10.  7|              press):~Mills EN, Valovirta E, Madsen C, Taylor SL, Vieths
100   II,     5. 10.  7|              Taylor SL, Vieths S, Anklam E, Baumgartner S, Koch P,
101   II,     5. 10.  7|               Frewer L, Madsen C, Botjes E, Crevel RWR, van Ree R (
102   II,     5. 10.  7|                 D, Zuidmeer L, Sodergren E, Sigurdardottir S, Lindner
103   II,     5. 10.  7|           Feighery C, Janssen FW, Méndez E, Mothes T, Troncone R, Wieser
104   II,     5. 11.  3|               around 30% (L Dotterud and E Falk, 1994). In Finland,
105   II,     5. 11.  3|             years of age (L Dotterud and E Falk, 1994). Sensitivity
106   II,     5. 11.  3|              2007;388:24-34.~L Dotterud, E Falk, Metal allergy in north
107   II,     5. 11.  3|                 R, Turjanmaa K, Varjonen E, Vuorela AM, Patch test
108   II,     5. 11.  3|                      F Pere a, O Bord o, E Silva, A Barr , M Gonç ,
109   II,     5. 11.  7|                 89:1121–1133.~ ~De Vries E, Bray FI, Coebergh JW, Parkin
110   II,     5. 12.  7|           Lucchini F, Zatonski WA, Negri E, La Vecchia C (2007): Worldwide
111   II,     5. 12.  7|               389.~de la Pena J, Brullet E, Sanchez-Hernandez E, Rivero
112   II,     5. 12.  7|             Brullet E, Sanchez-Hernandez E, Rivero M, Vergara M, Martin -~ ~
113   II,     5. 12.  7|          Lucchini F, Franceschi S, Negri E (1994): Worldwide patterns
114   II,     5. 12.  7|               Available at: htt ~ ~Negri E, Little D, Boiocchi M, La
115   II,     5. 14.  2|             Number of adults surveyed.~ ~e. Dentists and Other Oral
116   II,     5. 14.  8|                    http://www.who.int/gb/e/e_wha60.html] (article online,
117   II,     5. 14.  8|                  http://www.who.int/gb/e/e_wha60.html] (article online,
118   II,     6.  3.  2|         intestinal bacteria enterococci, E. coli, Klebsiella pneumoniae,
119   II,     6.  3.  2|          aeruginosa, enterobacteriaceae (E. Coli, Enterobacter, Klebsiella),
120   II,     6.  3.  3|                of viral hepatitis in the E.U.~ ~Hepatitis C is caused
121   II,     6.  3.  6|                of the years include both E. coli and VTEC. The most
122   II,     6.  4.  5|                 immunization programmes; e) reinforce the food monitoring
123   II,     7.  7    |                  Holder Y, Peden M, Krug E (Eds.) (2001): Injury Surveillance
124   II,     8.  2.  1|                50 (9), 667–677.~Emerson, E. (2005) Underweight, obesity
125   II,     8.  2.  1|           Research 49, 134143.~Emerson, E. and Hatton, C. (2007a).
126   II,     8.  2.  1|       Retardation 112, 140-150.~Emerson, E. and Hatton, C. (2007b).
127   II,     8.  2.  1|                 Bradley,V., Buntinx, W.H.E., Coulter, D.L., Craig,
128   II,     8.  2.  1|                  Y., Reeve, A., Snell, M.E., Spreat, S., Tasse, M.J.,
129   II,     9.  1.  1|                Saigal S, Nimrod C, Kelly E, et al (2002): Neonatal
130   II,     9.  1.  1|                 2004;191(3):700-7.~Garne E (2001): Perinatal mortality
131   II,     9.  1.  1|                  PA, Bakoula C, Hemminki E, Knudsen L, Levasseur M,
132   II,     9.  1.  2|            congenital heart disease) and e) practices regarding registration
133   II,     9.  1.  2|                  risk factor information e) full information on terminations
134   II,     9.  1.  2|               environmental pollution.~ ~e) Public health measures
135   II,     9.  1.  2|               Ritvanen A, Robert-Gnansia E, Siffel C, Stoll C and Mastroiacovo
136   II,     9.  1.  2|                  R, Scarano G, Calzolari E, Neville A, Cocchi G, Bianca
137   II,     9.  1.  2|               Ritvanen A, Robert-Gnansia E, Daltveit, A, Aneren G,
138   II,     9.  1.  2|                  S, Bianchi F, Calzolari E, De Walle H, Knill-Jones
139   II,     9.  1.  2|                   Dolk H, Loane M, Garne E, de Walle, H, Queisser-LuftA,
140   II,     9.  1.  2|               Vigan C, de Walle H, Garne E, Loane M, Pierini A, Garcia-Minaur
141   II,     9.  1.  2|           Tenconi R, Wiesel A, Calzolari E, Stone D (2004): "Towards
142   II,     9.  1.  2|                45, No 1, pp 52-58.~Garne E, Loane M, Nelen V, Bakker
143   II,     9.  1.  2|                 Vol 2, pp 165-169.~Garne E, Loane M, Dolk H, de Vigan
144   II,     9.  1.  2|                   Vol 25, pp 6-11.~Garne E, Loane M, de Vigan C et
145   II,     9.  1.  2|                 Vol 24, pp 908-12.~Garne E et al (1999): "Congenital
146   II,     9.  1.  2|                 Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk JJ (
147   II,     9.  1.  2|          McElhatton P, Reuvers M, Robert E, Rost van Tonningen M, Scialli
148   II,     9.  1.  2|                  D, Abramsky L, Alberman E, Scott JES (2000): “Socioeconomic
149   II,     9.  2.  7|              Levi F, La Vecchia C, Negri E, Lucchini F (2001): Childhood
150   II,     9.  2.  7|                Ståhl T, Wismar M, Ollila E, Lahtinen E, Leppo K (eds.) (
151   II,     9.  2.  7|             Wismar M, Ollila E, Lahtinen E, Leppo K (eds.) (2006):
152   II,     9.  3.  1|               009415~ ~Forsgren L, Beghi E, Õun A, Sillanpää M (2005):
153   II,     9.  3.  1| 1992Impotence091html.htm~ ~Niederlaender E (2006): Causes of death
154   II,     9.  3.  1|               2006~ ~Plümper T, Neumayer E (2006): The unequal burden
155   II,     9.  3.  2|                Saigal S, Nimrod C, Kelly E, et al (2002): Neonatal
156   II,     9.  3.  2|               2004;191(3):700-7.~ ~Garne E (2001): Perinatal mortality
157   II,     9.  3.  2|                  PA, Bakoula C, Hemminki E, Knudsen L, Levasseur M,
158   II,     9.  3.  3|                  gender-related issues” (e.g.violence).~ ~On 3 July
159   II,     9.  3.  3|       Dubois-Arber F, Jeannin A, Konings E, Paccaud F (1997): Increased
160   II,     9.  3.  3|                   Official Journal C 271 E , 12/11/2003 P. 0369 - 0374~
161   II,     9.  3.  3|                26:319-39.~Haavio-Mannila E, Kontula O (2001): Seksin
162   II,     9.  3.  3|            Helsinki:WSOY.~Haavio-Mannila E, Kontula O (2003) Sexual
163   II,     9.  3.  3|                Kaponen P, Haavio-Mannila E, Hemminki E (2007): Sexual
164   II,     9.  3.  3|               Haavio-Mannila E, Hemminki E (2007): Sexual health among
165   II,     9.  3.  3|         Pasquarella C, Limina RM, Cozani E, Fanti M, Cielo A, Greco
166   II,     9.  3.  3|                  Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel
167   II,     9.  4.  7|                 Jassem J, Senkus-Konefka E (2004): Report on 4th European
168   II,     9.  4.  7|                  2)~ ~Mukaetova-Ladinska E (2006): Towards living long
169   II,     9.  5.  6|                  1), pp. 47-59.~ ~Probyn E (2000): Sporting Bodies:
170   II,     9.  5.  6|           Risberg G, Hamber K, Johansson E (2006): Gender perspective
171  III,    10.  1.  3|                29(8):1076-1089.~Kuntsche E, Jordan MD (2006): Adolescent
172  III,    10.  1.  3|                Ashley MJ, Room R, Single E, Bondy S, Ferrence R, Giesbrecht
173  III,    10.  2.  1|            Ringborg U, Scully C, Siracka E, Storm H, Tubiana M, Tursz
174  III,    10.  2.  1|            Holder HD, Homel R, Österberg E, Rehm J, Room R and Rossow
175  III,    10.  2.  1|               Lushey C, Morleo M, Stokes E, Sumnall H, Witty K, Bellis
176  III,    10.  2.  1|                 F, Dickinson HO, Pienaar E, Campbell F, Schlesinger
177  III,    10.  2.  1|         Koivusilta L, Honkala S, Honkala E, Rimpelä A (2003): Toothbrushing
178  III,    10.  2.  1|                    http://www.who.int/gb/e/e_wha60.html] (accessed
179  III,    10.  2.  1|                  http://www.who.int/gb/e/e_wha60.html] (accessed on
180  III,    10.  2.  1|               activity are still rare.~ ~e) Data from accession countries~
181  III,    10.  2.  1|                Saba A, Perrone D, Cialfa E, D'Amicis A (2001): Food
182  III,    10.  2.  1|              physical activity (OJ C 250 E, 25.10.2007, p. 93White
183  III,    10.  2.  1|                  only 7 are the same (i. e.: eat plenty of).~Two approaches
184  III,    10.  2.  1|               Demarest S, Gisle L, Hesse E, Miermans PJ, Tafforeau
185  III,    10.  2.  1|             Scarpino V, Zuccaro P, Negri E, Apolone G, La Vecchia C (
186  III,    10.  2.  1|                   Petkevičienė J, Šakytė E, Kriaučionienė V, Paalanen
187  III,    10.  2.  1|                    Mhurchu C, Kalamara E, Shayeghi M, Rigby NJ, Nishida
188  III,    10.  2.  1|              October 2007).~ ~Johannsson E, Arngrimsson SA, Thorsdottir
189  III,    10.  2.  1|          Jotangia D, Moody A, Stamatakis E, Wardle H (2005): Obesity
190  III,    10.  2.  1|               112:1431–1433.~ ~Kapantais E, Haralambides V, Tzotzas
191  III,    10.  2.  1|               Suppl. 1):S71.~ ~Kapantais E, Tzotzas E, Loannidis I,
192  III,    10.  2.  1|                     Kapantais E, Tzotzas E, Loannidis I, Mortoglou
193  III,    10.  2.  1|             Agoston H, Balázs A, Mozsáry E, Vitrai J, Hermann D, Boros
194  III,    10.  2.  1|                  Panagi A, Chrictodoulou E, Kafatos A (2005): Prevalence
195  III,    10.  2.  1|                105:260275.~ ~Stamatakis E, Primatesta P, Chinn S,
196  III,    10.  2.  1|              Chinn S, Rona R, Falascheti E (2005): Overweight and obesity
197  III,    10.  2.  1|                     Summerbell C, Waters E, Edmunds LD, Kelly S, Brown
198  III,    10.  2.  1|                726.~ ~Szponar L, Rychlik E, Oltarzewski Ml (2003):
199  III,    10.  2.  1|             Szponar L, Sekula W, Rychlik E, Oltarzewski M, Figurska
200  III,    10.  2.  1|                  ece/ac/ece.ac.21.2002.9.e.pdf).~ ~Visscher TLS, Viet
201  III,    10.  2.  1|                  Elmadfa I, Weichselbaum E (eds) (2005): European Nutrition
202  III,    10.  2.  1|              Zhang JX, Welch AA, Spencer E, Stripp C, Overvad K, Clavel-Chapelon
203  III,    10.  2.  1|                  F, Casagrande C, Riboli E (2002): Consumption of vegetables,
204  III,    10.  2.  1|                Lagiou A, Slimani N, Lund E, Chirlaque MD, Vasilopoulou
205  III,    10.  2.  1|               Chirlaque MD, Vasilopoulou E, Zavitsanos X, Berrino F,
206  III,    10.  2.  1|                Schulz M, Hemon B, Riboli E (2002): Consumption of dairy
207  III,    10.  2.  1|           Slimani N, Mattisson I, Lundin E, McTaggart A, Allen NE,
208  III,    10.  2.  1|               Skeie G, Tormo MJ, Ardanaz E, Charrondiere UR, Riboli
209  III,    10.  2.  1|                  Charrondiere UR, Riboli E (2002): Soy product consumption
210  III,    10.  2.  1|                   Linseisen J, Bergstrom E, Gafa L, Gonzalez CA, Thiebaut
211  III,    10.  2.  1|                 Clavel-Chapelon F, Kesse E, Miller AB, Schulz M, Botsi
212  III,    10.  2.  1|               1242.~ ~Linseisen J, Kesse E, Slimani N, Bueno-De-Mesquita
213  III,    10.  2.  1|          Giurdanella MC, Norat T, Riboli E. (2002b): Meat consumption
214  III,    10.  2.  1|           Chirlaque MD, Pozo BG, Ardanaz E, Mattisson I, Pettersson
215  III,    10.  2.  1|                 Clavel-Chapelon F, Kesse E, Boeing H, Klipstein-Grobusch
216  III,    10.  2.  1|             Trichopoulou A, Vasilopoulou E, Bellos G, Pala V, Masala
217  III,    10.  2.  1|               Skeie G, Slimani N, Riboli E (2006): Dietary intake of
218  III,    10.  2.  1|                  Sieri S, Agudo A, Kesse E, Klipstein-Grobusch K, San-Jose
219  III,    10.  2.  1|            Kolyva M, Saieva C, Celentano E, Ocke MC, Peeters PH, Brustad
220  III,    10.  2.  1|         Mattisson I, Weinehall L, Riboli E, Slimani N (2002): Patterns
221  III,    10.  2.  1|              1287-1296.~ ~Welch AA, Lund E, Amiano P, Dorronsoro M,
222  III,    10.  2.  4|         Organisation~APOE~Apolipoprotein E~MTHFR~Meth ~ ~
223  III,    10.  2.  4|           Collins FS, Patrinos A, Jordan E, Chakravarti A., Gesteland
224  III,    10.  2.  4|           Johnson J, Cox N J, Wichmann H E, Wienker T F, Schulze J,
225  III,    10.  2.  4|                  F, Schulze J, Schwarz P E, Lindner T H (2007): A German
226  III,    10.  2.  4|                Klein C, Rodriguez-Cerezo E (2003): Institute of Prospective
227  III,    10.  2.  4|                 MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P,
228  III,    10.  2.  4|                 Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong
229  III,    10.  2.  4|                   Vol 447:661-678~ ~Zika E, Papatryfon I, Wolf O, Gómez-Barbero
230  III,    10.  2.  5|            Osmond C, Forsén TJ, Kajantie E, Eriksson JG (2005): Trajectories
231  III,    10.  2.  5|          Eriksson JG, Osmond C, Kajantie E, Forsén TJ, Barker DJP (
232  III,    10.  3.  1|              Ruano-Ravina A, Ruosteenoja E, A Schaffrath Rosario A,
233  III,    10.  3.  1|           Tirmarche M, Tomáek L, Whitley E, Wichmann HE, Doll R, (2005):
234  III,    10.  4.  2|               irradiation of foodstuffs; e) RASFF and emergencies:
235  III,    10.  4.  2|                  including Verotoxigenic E. coli;~• Campylobacter;~•
236  III,    10.  4.  2|                      Shellfish~Hepatitis E virus~ ~ ~Pig~ ~ ~ ~Table
237  III,    10.  4.  2|                High, in adults~Hepatitis E virus~ ~Jaundice~ ~High,
238  III,    10.  4.  2|               facilities and equipment; (e) that they have the legal
239  III,    10.  4.  2|        Autoridade de Segurança Alimentar e Económica~Portugal~The nd~
240  III,    10.  4.  5|                for faecal contamination, E. Coli and Intestinal Enterococci,
241  III,    10.  4.  5|                  have been simplified to E. coli and intestinal enterococci,
242  III,    10.  5.  1|                Bygren, L O. Johansson, S E. Visiting the cinema, concerts,
243  III,    10.  5.  1|                 Rogers MAM, Zaragoza-Lao E: Happiness and children’
244  III,    10.  5.  1|                 2001, S. II-10~Shenassa, E., Liebhaber, A., Ezeamama,
245  III,    10.  5.  1|                aria nelle scuole europee e sue implicazioni sulla salute
246  III,    10.  5.  2|                on 2 August 2007).~ ~Roel E et al. (2005): Clinically
247  III,    10.  6.  1|             Currie C, Gabhainn S, Godeau E, Roberts C, Smith R, Currie
248  III,    10.  6.  1|                  R, McLeod J, Wethington E. The cost of caring: a perspective
249  III,    10.  6.  1|                ahead of print]~Shenassa, E., Liebhaber, A., Ezeamama,
250  III,    10.  6.  2|              Kunst AE, Borrell C, Breeze E, Cambois E, Costa G, Geurts
251  III,    10.  6.  2|             Borrell C, Breeze E, Cambois E, Costa G, Geurts JJM, Lahelma
252  III,    10.  6.  2|             Costa G, Geurts JJM, Lahelma E, Van Oyen H, Rasmussen NK,
253  III,    10.  6.  2|                 H, Rasmussen NK, Regidor E, Spadea T, and Mackenbach
254   IV,    11.  5.  5|                written by Michel Goldman e Kathryn Wood (Goldman and
255   IV,    11.  6.  5|                13-16.~ ~Brook R, McGlynn E et al. (1996): "Quality
256   IV,    11.  6.  5|                     Culyer AJ, Doorslaer E et al. (1992): "Comment:
257   IV,    11.  6.  5|            University.~ ~Ettelt S, Nolte E et al. (2006): Health care
258   IV,    11.  6.  5|                     Kanavos P, Mossialos E (1999): "International comparisons
259   IV,    11.  6.  5|             Policy 4(2): 122-6.~ ~Kelley E, Hurst J (2006): Health
260   IV,    11.  6.  5|              Community. W.W. Holland and E. Mossialos. Aldershot: Ashgate~ ~
261   IV,    11.  6.  5|                 11: 199205.~ ~Mossialos E, Brogan D et al. (2006): "
262   IV,    11.  6.  5|                 59(3): 3-25.~ ~Mossialos E, Merkur S et al. (2006):
263   IV,    11.  6.  5|                Institutions.~ ~Mossialos E, Dixon A Eds. (2002): Funding
264   IV,    11.  6.  5|                and Policies.~ ~Mossialos E, Dixon A et al. (2000): "
265   IV,    11.  6.  5|                  320: 197-8.~ ~Mossialos E, Le Grand J Eds. (1999):
266   IV,    11.  6.  5|                   Aldershot.~ ~Mossialos E, Mrazek M et al. (2004):
267   IV,    11.  6.  5|               Pharmaceuticals in Europe. E. Mossialos, M. Mrazek and
268   IV,    11.  6.  5|            University Press.~ ~Mossialos E, Thomson S (2004): Voluntary
269   IV,    11.  6.  5|                and Policies.~ ~Mossialos E, Walley T et al. (2004):
270   IV,    11.  6.  5|          efficiency, equity and quality. E. Mossialos, T. Walley and
271   IV,    11.  6.  5|                and Policies.~ ~Mossialos E, Walley T et al. (2005): "
272   IV,    11.  6.  5|                93.~ ~Mrazek M, Mossialos E (2004): Regulating pharmaceutical
273   IV,    11.  6.  5|          efficiency, equity and quality. E. Mossialos, M. Mrazek and
274   IV,    11.  6.  5|                 and development.~ ~Nolte E, McKee M (2005): Does Health
275   IV,    11.  6.  5|              Trust~ ~Oliver A, Mossialos E (2004): "Equity of access
276   IV,    11.  6.  5|                    Perleth M, Jakubowski E et al. (2001): "What is '
277   IV,    11.  6.  5|                care: options for Europe. E. Mossialos, A. Dixon, J.
278   IV,    11.  6.  5|                care: options for Europe. E. Mossialos, A. Dixon, J.
279   IV,    11.  6.  5|                   Robinson R, Jakubowski E et al. (2005): Organization
280   IV,    11.  6.  5|                Figueras, R. Robinson and E. Jakubowski. Copenhagen,
281   IV,    11.  6.  5|                     Thomson S, Mossialos E et al. (2003): Cost sharing
282   IV,    11.  6.  5|                     Thomson S, Mossialos E et al. (2004): Health and
283   IV,    11.  6.  5|                   75-98.~ ~van Doorslaer E, Koolman X et al. (2004): "
284   IV,    11.  6.  5|                 629-647.~ ~van Doorslaer E, Masseria C et al. (2004):
285   IV,    11.  6.  5|             Paris, OECD.~ ~Van Doorslaer E, Wagstaff A et al. (1999): "
286   IV,    11.  6.  5|                Wagstaff A, van Doorslaer E et al., Eds. (1999): Equity
287   IV,    11.  6.  5|             Press.~ ~Walley T, Mossialos E (2004): Financial incentives
288   IV,    11.  6.  5|               Pharmaceuticals in Europe. E. Mossialos, M. Mrazek and
289   IV,    12.  1    |                 in Articles 3, where the E.U., is to make “a contribution
290   IV,    12.  1    |         protection” (art.3p) in pursuing E.U. priority objectives and
291   IV,    12.  5    |               data)~- Disease registers (e. g. cancer, myocardial infarction,
292   IV,    12.  5    |             stroke)~- Sentinel Networks (e. g. diseases not under mandatory
293   IV,    12.  5    |             Active Surveillance Measures(e. g. Notifiable Infectious
294   IV,    12.  5    |                     Administrative data (e. g. health insurance data,
295   IV,    12.  5    |              care staff)~- Process data (e. g. data on health care
296   IV,    12.  5    |             studies~- Data from Surveys (e. g. population representative
297   IV,    12. 10    |                 FA C T S A N D A D V I C E~about smoking and stopping~http df~
298   IV,    12. 10    |                 some cases federal) laws e. g. against smoking at public
299   IV,    12. 10    |                children/adolescents (see e. g. www o) including quit-lines (
300   IV,    12. 10    |          non-governmental organisations (e. g. German Medical Association/
301   IV,    12. 10    |                     since 2004): targets e. g. prevention of diabetes
302   IV,    12. 10    |           improved local infrastructure (e. g. cycle paths, public
303   IV,    12. 10    |                 self-help organizations (e. g. drug counselling centres).~ ~
304   IV,    12. 10    |                different sorts of drugs (e. g. “Quit the shit”-program
305   IV,    12. 10    |               focus on health behaviour (e. g. information concerning
306   IV,    12. 10    |            ionising radiation there are, e. g., X-ray diagnostics in
307   IV,    12. 10    |       implemented early warning systems (e. g. on heat waves) that
308   IV,    12. 10    |                 in sozialen Brennpunkten E&C) htt ; In cooperation
309   IV,    12. 10    |               additional information see e. g. German Registry for
310   IV,    12. 10    |                  bioethical subjects see e. g. Federal Ministry of
311   IV,    12. 10    |          Ministerial Decision 37411/1829/E 103 defining the relevant
312   IV,    12. 10    |                been partly funded by the E.U~o Common Ministerial Decision
313   IV,    12. 10    |           control in compliance with the E.U Regulation 93/99.~o Common
314   IV,    13.Acr    |            Quality Adjusted Life Years~S&E~Science and Engineering~ ~ ~
315   IV,    13.  7.  2|               science and engineering (S&E) graduates, who now make
316   IV,    13.  7.  2|                stronger performance in S&E graduates and broadband
317   IV,    13.  9    |                 2002; 360: 1347-60.~Fazi E, Smith J (2006): Civil Dialogue: